FDA Approves Evkeeza for Youngest Children with Rare Genetic Cholesterol Disorder
Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Evkeeza (evinacumab-dgnb) for treating children aged 1 to under 5 years with homozygous…
Read More...
Read More...
